Recombinant Human ErbB2/Her2 Fc Chimera Protein, CF

1 μg/lane of Recombinant Human ErbB2 Fc Chimera was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by silver staining, showing major bands at 125-130 kDa and 220-250 kDa, respectively.

Recombinant human ErB2 / Her2 (1129-ER) blocks anti-ErbB2 mediated inhibition of SK-BR-3 human breast cancer proliferation. The ED50 for this effect is 0.3-1.2 µg/mL in the presence of 0.6 µg/mL Anti-Human ErbB2/Her2 Monoclonal Antibody (Trastuzumab, MAB9589).

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human ErbB2/Her2 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to block anti-ErbB2 mediated inhibition of SK‑BR‑3 human breast cancer cell proliferation. Brodowicz, T. et al. (1997) Int. J. Cancer 73:875. The ED₅₀ for this effect is 0.3-1.2 μg/mL in the presence of 0.6 µg/mL Anti-Human ErbB2/Her2 Monoclonal Antibody (Trastuzumab, Catalog # MAB9589).
• Source: Mouse myeloma cell line, NS0-derived human ErbB2/Her2 protein
  

  Human Erb B2 (Thr23-Thr652) Accession # NP_004439	IEGRMD	Human IgG1 (Pro100-Lys330)	6 His-tag
  N-terminus			C-terminus

• Accession #: NP_004439
• N-terminal Sequence: Thr23
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: ERBB2
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 96.8 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 125-130 kDa, reducing conditions
  220-250 kDa, non-reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human ErbB2/Her2 Fc Chimera Protein, CF

• CD340 antigen
• CD340
• c-erb B2/neu protein
• EC 2.7.10
• EGFR2
• ErbB2
• HER2
• HER-2
• HER2EC 2.7.10.1
• herstatin
• Metastatic lymph node gene 19 protein
• MLN 19
• MLN19
• Neu Oncogene
• NEUHER-2/neu
• neuroblastoma/glioblastoma derived oncogene homolog
• NGL
• NGLTKR1
• p185erbB2
• Proto-oncogene c-ErbB-2
• Proto-oncogene Neu
• receptor tyrosine-protein kinase erbB-2
• TKR1
• Tyrosine kinase-type cell surface receptor HER2
• v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2(neuro/glioblastoma derived oncogene homolog)
• v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastomaderived oncogene homolog (avian)

Background

ErbB2, also called Neu and Her2 (human epidermal growth factor receptor 2), is a type I membrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors. ErbB family members serve as receptors for the epidermal growth factor (EGF) family of growth factors. ErbB2 is widely expressed in epithelial cells and has also been found to be over-expressed in a large number of breast carcinomas. Among ErbB family members, ErbB2 is unique in that it has no identified ligands. Rather, ErbB2 heterodimerizes with the other members of the ErbB family (ErbB1 (EGFR), ErbB3, ErbB4) to form higher affinity signaling complexes. Because ErbB3 contains a defective kinase domain, the kinase domain of ErbB2 is responsible for initiating the tyrosine phosphorylation signal through the heterodimeric receptor. It has been found that a discrete three amino acid signal in the ErbB3 cytoplasmic domain is critical for transactivation of ErbB2. Interestingly, this same three amino acid signal has also been found in ErbB1 and ErbB4. Phosphoinositide 3-kinase has been shown to play a role in ErbB2 signal transduction. The cytoplasmic domain of ErbB2 has been shown to associate with beta-catenin and plakoglobin. Human ErbB2 consists of 1255 amino acids (aa) with a 21 aa signal sequence, a 631 aa extracellular domain, a 23 aa transmembrane region, and a 580 aa cytoplasmic domain. ErbB2 can be shed from the cell surface by proteolytic cleavage by an unidentified protease. ErbB2 appears to play roles in development, cancer, communication at the neuromuscular junction and regulation of cell growth and differentiation (1-10).

1. Coussens, L. et. al. (1985) Science 230:1132.
2. Yamamoto, T. et. al. (1986) Nature 319:230.
3. Kanai, Y. et. al. (1995) Biochem. Biophys. Res. Commun. 208:1067.
4. Codony-Servat, J. et. al. (1999) Cancer Res. 59:1196.
5. Carraway, K.L. 3^rd et. al.  (1994) J. Biol. Chem. 269:14303.
6. Emkey, R. and C.R. Kahn (1997) J. Biol. Chem. 272:31172.
7. Schaefer, G. et. al. (1999) J. Biol. Chem. 274:859.
8. Schlessinger, J. (2000) Cell 103:211.
9. Hellyer, N.J. et. al. (2001) J. Biol. Chem. 276:42153.
10. Daly, R.J. (1999) Growth Factors 16:255.

Publications for ErbB2/Her2 (1129-ER)(55)

Publications using 1129-ER

• M Po?niak, D ?ukowska, A G?daj, MA Krzy?cik, N Por?bska, M Zakrzewska, J Otlewski, ? Opali?ski The Significance of Cell Surface N-Glycosylation for Internalization and Potency of Cytotoxic Conjugates Targeting Receptor Tyrosine Kinases International Journal of Molecular Sciences, 2022;23(15):. 2022 [PMID: 35955648] (Bioassay, Human)
• N Hebbar, R Epperly, A Vaidya, U Thanekar, SE Moore, M Umeda, J Ma, SL Patil, D Langfitt, S Huang, C Cheng, JM Klco, S Gottschalk, MP Velasquez CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells Nature Communications, 2022;13(1):587. 2022 [PMID: 35102167] (Flow Cytometry, Human)
• J Garousi, H Ding, E von Wittin, T Xu, A Vorobyeva, M Oroujeni, A Orlova, S Hober, T Gräslund, V Tolmachev Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein Pharmaceutics, 2021;13(11):. 2021 [PMID: 34834262] (Bioassay, Human)
• N Stoup, M Liberelle, C Schulz, S Cavdarli, R Vasseur, R Magnez, F Lahdaoui, N Skrypek, F Peretti, F Frénois, X Thuru, P Melnyk, N Renault, N Jonckheere, N Lebègue, I Van Seunin The EGF Domains of MUC4 Oncomucin Mediate HER2 Binding Affinity and Promote Pancreatic Cancer Cell Tumorigenesis Cancers, 2021;13(22):. 2021 [PMID: 34830899] (Bioassay, Human)
• R Chidiac, M Abedin, G Macleod, A Yang, PE Thibeault, LL Blazer, JJ Adams, L Zhang, H Roehrich, HN Jo, S Seshagiri, SS Sidhu, HJ Junge, S Angers A Norrin/Wnt surrogate antibody stimulates endothelial cell barrier function and rescues retinopathy Embo Molecular Medicine, 2021;0(0):e13977. 2021 [PMID: 34105895] (Bioassay, Human)
• H Ding, T Xu, J Zhang, V Tolmachev, M Oroujeni, A Orlova, T Gräslund, A Vorobyeva Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution Pharmaceutics, 2021;13(3):. 2021 [PMID: 33806887] (Surface Plasmon Resonance, Human)
• SF Yuan, SM Brooks, AW Nguyen, WL Lin, TG Johnston, JA Maynard, A Nelson, HS Alper Bioproduced Proteins On Demand (Bio-POD) in hydrogels using Pichia pastoris Bioactive materials, 2021;6(8):2390-2399. 2021 [PMID: 33553823] (Bioassay, Hamster)
• T Xu, H Ding, A Vorobyeva, M Oroujeni, A Orlova, V Tolmachev, T Gräslund Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model Cancers, 2020;13(1):. 2020 [PMID: 33396753] (Bioassay, Human)
• RA Youness, AZ Gad, K Sanber, YJ Ahn, GJ Lee, E Khallaf, HM Hafez, AA Motaal, N Ahmed, MZ Gad Targeting hydrogen sulphide signaling in breast cancer Journal of advanced research, 2021;27(0):177-190. 2021 [PMID: 33318876] (Bioassay, Human)
• S Dengl, K Mayer, F Bormann, H Duerr, E Hoffmann, B Nussbaum, M Tischler, M Wagner, A Kuglstatte, L Leibrock, C Buldun, G Georges, U Brinkmann Format chain exchange (FORCE) for high-throughput generation of bispecific antibodies in combinatorial binder-format matrices Nat Commun, 2020;11(1):4974. 2020 [PMID: 33009381] (ELISA Capture, N/A)
• T Kondo, Y Iwatani, K Matsuoka, T Fujino, S Umemoto, Y Yokomaku, K Ishizaki, S Kito, T Sezaki, G Hayashi, H Murakami Antibody-like proteins that capture and neutralize SARS-CoV-2 Sci Adv, 2020;0(0):. 2020 [PMID: 32948512] (Affinity, Human)
• AK Wege, N Kirchhamme, LV Kazandjian, S Prassl, M Brandt, G Piendl, O Ortmann, S Fischer, G Brockhoff A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM) J Transl Med, 2020;18(1):316. 2020 [PMID: 32799890] (Bioassay, Human)
• AK Wege, N Kirchhamme, LV Kazandjian, S Prassl, M Brandt, G Piendl, O Ortmann, S Fischer, G Brockhoff A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM) J Transl Med, 2020;18(1):316. 2020 [PMID: 32799890] (ELISA Capture, Human)
• M Hegde, SK Joseph, F Pashankar, C DeRenzo, K Sanber, S Navai, TT Byrd, J Hicks, ML Xu, C Gerken, M Kalra, C Robertson, H Zhang, A Shree, B Mehta, O Dakhova, VS Salsman, B Grilley, A Gee, G Dotti, HE Heslop, MK Brenner, WS Wels, S Gottschalk, N Ahmed Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma Nat Commun, 2020;11(1):3549. 2020 [PMID: 32669548] (CAR-T (Flow Cytometry), Human)
• Z Dai, XN Zhang, F Nasertorab, Q Cheng, J Li, BB Katz, G Smbatyan, H Pei, SG Louie, HJ Lenz, RC Stevens, Y Zhang Synthesis of site-specific antibody-drug conjugates by ADP-ribosyl cyclases Sci Adv, 2020;6(23):eaba6752. 2020 [PMID: 32537509] (ELISA Capture, Human)
• M Crauwels, N Van Vaeren, B Kulaya Nee, C Vincke, M D'Huyvette, N Devoogdt, S Muylderman, C Xavier Reshaping Nanobodies for affinity purification on protein A N Biotechnol, 2020;0(0):. 2020 [PMID: 32001339] (Surface Plasmon Resonance (SPR, Human)
• T Kadonosono, W Yimchuen, Y Ota, K See, T Furuta, T Shiozawa, M Kitazawa, Y Goto, A Patil, T Kuchimaru, S Kizaka-Kon Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use Sci Rep, 2020;10(1):891. 2020 [PMID: 31964960] (Direct ELISA, Human)
• CL Parker, TM Jacobs, JT Huckaby, D Harit, SK Lai Efficient and Highly Specific Gene Transfer Using Mutated Lentiviral Vectors Redirected with Bispecific Antibodies MBio, 2020;11(1):. 2020 [PMID: 31964730] (ELISA (Capture), Human)
• M Liberelle, R Magnez, X Thuru, Y Bencheikh, S Ravez, C Quenon, AS Drucbert, C Foulon, P Melnyk, IV Seuningen, N Lebègue MUC4-ErbB2 Oncogenic Complex: Binding studies using Microscale Thermophoresis Sci Rep, 2019;9(1):16678. 2019 [PMID: 31723153] (Bioassay, Human)
• J Medina-Ech, M Hinterberg, M Testori, M Geiger, R Giessel, B Bathke, R Kassub, F Gräbnitz, G Fiore, ST Wennier, P Chaplin, M Suter, H Hochrein, H Lauterbach Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies Nat Commun, 2019;10(1):5041. 2019 [PMID: 31695037] (ELISA Capture, Mouse)
• S Ahn, J Li, C Sun, K Gao, K Hirabayash, H Li, B Savoldo, R Liu, G Dotti Cancer immunotherapy with T cells carrying bispecific receptors that mimic antibodies Cancer Immunol Res, 2019;0(0):. 2019 [PMID: 30842091] (CAR-T (Bioassay), Human)
• SJ Tobin, DL Wakefield, V Jones, X Liu, D Schmolze, T Jovanovi?- Single molecule localization microscopy coupled with touch preparation for the quantification of trastuzumab-bound HER2 Sci Rep, 2018;8(1):15154. 2018 [PMID: 30310083] (ICC, Human)
• CW Helsen, JA Hammill, VWC Lau, KA Mwawasi, A Afsahi, K Bezverbnay, L Newhook, DL Hayes, C Aarts, B Bojovic, GF Denisova, JM Kwiecien, I Brain, H Derocher, K Milne, BH Nelson, JL Bramson The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity Nat Commun, 2018;9(1):3049. 2018 [PMID: 30076299]
• M Pruszynski, CM Kang, E Koumariano, G Vaidyanath, MR Zalutsky d-Amino Acid Peptide Residualizing Agents for Protein Radioiodination: Effect of Aspartate for Glutamate Substitution Molecules, 2018;23(5):. 2018 [PMID: 29783774] (Bioassay, N/A)
• M Kahl, F Settele, P Knick, U Haupts, E Bosse-Doen Mabfilin and Fabfilin - New antibody-scaffold fusion formats for multispecific targeting concepts Protein Expr. Purif., 2018;0(0):. 2018 [PMID: 29704557] (Bioassay)
• V Tolmachev, TJ Grönroos, CB Yim, J Garousi, Y Yue, S Grimm, J Rajander, A Perols, M Haaparanta, O Solin, R Ferdani, A Orlova, CJ Anderson, AE Karlström Molecular design of radiocopper-labelled Affibody molecules Sci Rep, 2018;8(1):6542. 2018 [PMID: 29695813] (Surface Plasmon Resonance, Human)
• I Correa, KM Ilieva, S Crescioli, S Lombardi, M Figini, A Cheung, JF Spicer, ANJ Tutt, FO Nestle, P Karagianni, KE Lacy, SN Karagianni Evaluation of Antigen-Conjugated Fluorescent Beads to Identify Antigen-Specific B Cells Front Immunol, 2018;9(0):493. 2018 [PMID: 29628923] (Protein Array, Human)
• AW Nguyen, KC Le, JA Maynard Identification of high affinity HER2 binding antibodies using CHO Fab surface display Protein Eng. Des. Sel., 2018;31(3):91-101. 2018 [PMID: 29566240] (ELISA Capture, Human)
• J Lee, HA Kang, JS Bae, KD Kim, KH Lee, KJ Lim, MJ Choo, SJ Chang Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses MAbs, 2018;0(0):1-102. 2018 [PMID: 29482416] (ELISA Capture, Human)
• Bielamowicz K, Fousek K, Byrd T, Samaha H, Mukherjee M, Aware N, Wu M, Orange J, Sumazin P, Man T, Joseph S, Hegde M, Ahmed N Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol, 0;20(4):506-518. 0 [PMID: 29016929] (CAR-T (Bioassay), Human)
• N Shinozaki, R Hashimoto, K Fukui, S Uchiyama Efficient generation of single domain antibodies with high affinities and enhanced thermal stabilities Sci Rep, 2017;7(1):5794. 2017 [PMID: 28725057] (Bioassay, N/A)
• B Petrovic, T Gianni, V Gatta, G Campadelli Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins PLoS Pathog., 2017;13(4):e1006352. 2017 [PMID: 28423057] (Bioassay, Human)
• J Tobias, J Jasinska, K Baier, M Kundi, N Ede, C Zielinski, U Wiedermann Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide BMC Cancer, 2017;17(1):118. 2017 [PMID: 28183282] (Bioassay, Mouse)
• A Highly Diverse and Functional Na�ve Ubiquitin Variant Library for Generation of Intracellular Affinity Reagents J. Mol. Biol., 2016;0(0):. 2016 [PMID: 27887869] (Direct ELISA, Human)
• Sachdev S Sidhu A Highly Diverse and Functional Na�ve Ubiquitin Variant Library for Generation of Intracellular Affinity Reagents J. Mol. Biol., 2016;0(0):. 2016 [PMID: 27887869] (Western Blot)
• Peng Dai Salt Effect Accelerates Site-Selective Cysteine Bioconjugation ACS Cent Sci, 2016;2(9):637-646. 2016 [PMID: 27725962] (Bioassay)
• Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai S, Wakefield A, Fousek K, Bielamowicz K, Chow K, Brawley V, Byrd T, Krebs S, Gottschalk S, Wels W, Baker M, Dotti G, Mamonkin M, Brenner M, Orange J, Ahmed N Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J Clin Invest, 0;126(8):3036-52. 0 [PMID: 27427982] (CAR-T (Bioassay), Human)
• F Selis, G Focà, A Sandomenic, C Marra, C Di Mauro, G Saccani Jo, S Scaramuzza, A Politano, R Sanna, M Ruvo, G Tonon Pegylated Trastuzumab Fragments Acquire an Increased in Vivo Stability but Show a Largely Reduced Affinity for the Target Antigen Int J Mol Sci, 2016;17(4):. 2016 [PMID: 27043557] (ELISA (Capture), Human)
• Kanojia D, Balyasnikova I, Morshed R, Frank R, Yu D, Zhang L, Spencer D, Kim J, Han Y, Yu D, Ahmed A, Aboody K, Lesniak M Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases. Stem Cells, 2015;33(10):2985-94. 2015 [PMID: 26260958] (Bioassay, Human)
• Leung K, Batey S, Rowlands R, Isaac S, Jones P, Drewett V, Carvalho J, Gaspar M, Weller S, Medcalf M, Wydro M, Pegram R, Mudde G, Bauer A, Moulder K, Woisetschlager M, Tuna M, Haurum J, Sun H A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis. Mol Ther, 2015;23(11):1722-33. 2015 [PMID: 26234505] (Bioassay, Human)
• Zhou Q, Uhlig K, Muth A, Kimpel J, Levy C, Munch R, Seifried J, Pfeiffer A, Trkola A, Coulibaly C, von Laer D, Wels W, Hartwig U, Verhoeyen E, Buchholz C Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors. J Immunol, 2015;195(5):2493-501. 2015 [PMID: 26232436] (Flow Cytometry, Human)
• VanSeggelen H, Hammill J, Dvorkin-Gheva A, Tantalo D, Kwiecien J, Denisova G, Rabinovich B, Wan Y, Bramson J T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice. Mol Ther, 2015;23(10):1600-10. 2015 [PMID: 26122933] (Bioassay, Mouse)
• Lin C, Pan I, Li Y, Pan Y, Lin M, Lu Y, Wu H, Chu C The adjuvant effects of high-molecule-weight polysaccharides purified from Antrodia cinnamomea on dendritic cell function and DNA vaccines. PLoS ONE, 2015;10(2):e0116191. 2015 [PMID: 25723174] (Bioassay, Mouse)
• Schonfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bonig H, Kohl U, Kloess S, Kohler S, Holtgreve-Grez H, Jauch A, Schmidt M, Schubert R, Kuhlcke K, Seifried E, Klingemann H, Rieger M, Tonn T, Grez M, Wels W Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther, 2015;23(2):330-8. 2015 [PMID: 25373520] (Flow Cytometry, Human)
• Nilvebrant J, Astrand M, Georgieva-Kotseva M, Bjornmalm M, Lofblom J, Hober S Engineering of bispecific affinity proteins with high affinity for ERBB2 and adaptable binding to albumin. PLoS ONE, 2014;9(8):e103094. 2014 [PMID: 25089830] (Surface Plasmon Resonance, Human)
• Hussain , Sajid, Rodriguez-Fernandez , Maria, Braun , Gary B, Doyle , Francis, Ruoslahti , Erkki Quantity and accessibility for specific targeting of receptors in tumours. Sci Rep, 2014;4(0):5232. 2014 [PMID: 24912981] (Bioassay, Human)
• Gu J, Yang J, Chang Q, Lu X, Wang J, Chen M, Ghayur T, Gu J Identification of anti-ErbB2 dual variable domain immunoglobulin (DVD-Ig) proteins with unique activities. PLoS ONE, 2014;9(5):e97292. 2014 [PMID: 24824849] (Bioassay, Human)
• Kang , Jeffrey, Poovassery , Jayakuma, Bansal , Pankaj, You , Sungyong, Manjarres , Isabel M, Ober , Raimund, Ward , E Sally Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells. MAbs, 2014;6(2):340-53. 2014 [PMID: 24492289] (Bioassay, N/A)
• Hegde M, Corder A, Chow K, Mukherjee M, Ashoori A, Kew Y, Zhang Y, Baskin D, Merchant F, Brawley V, Byrd T, Krebs S, Wu M, Liu H, Heslop H, Gottschalk S, Yvon E, Ahmed N Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther, 0;21(11):2087-101. 0 [PMID: 23939024] (Bioassay, Human)
• Frese , Katrin, Eisenmann , Meike, Ostendorp , Ralf, Brocks , Bodo, Pabst , Stefan An automated immunoassay for early specificity profiling of antibodies. MAbs, 2013;5(2):279-87. 2013 [PMID: 23412646] (Bioassay, Human)
• Axup , Jun Y, Bajjuri , Krishna, Ritland , Melissa, Hutchins , Benjamin, Kim , Chan Hyu, Kazane , Stephani, Halder , Rajkumar, Forsyth , Jane S, Santidrian , Antonio, Stafin , Karin, Lu , Yingchun, Tran , Hon, Seller , Aaron J, Biroc , Sandra L, Szydlik , Aga, Pinkstaff , Jason K, Tian , Feng, Sinha , Subhash, Felding-Habermann , Brunhild, Smider , Vaughn V, Schultz , Peter G Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A, 2012;109(40):16101-6. 2012 [PMID: 22988081] (Bioassay, N/A)
• Feldwisch J, Tolmachev V, Lendel C, Herne N, Sjoberg A, Larsson B, Rosik D, Lindqvist E, Fant G, Hoiden-Guthenberg I, Galli J, Jonasson P, Abrahmsen L Design of an optimized scaffold for affibody molecules. J. Mol. Biol., 2010;398(2):232-47. 2010 [PMID: 20226194] (Bioassay)
• Serpe M, Umulis D, Ralston A, Chen J, Olson DJ, Avanesov A, Othmer H, O'Connor MB, Blair SS The BMP-binding protein Crossveinless 2 is a short-range, concentration-dependent, biphasic modulator of BMP signaling in Drosophila. Dev. Cell, 2008;14(6):940-53. 2008 [PMID: 18539121] (Bioassay, Drosophila)
• Gonzalez RM, Seurynck-Servoss SL, Crowley SA Development and validation of sandwich ELISA microarrays with minimal assay interference. J. Proteome Res., 2008;7(6):2406-14. 2008 [PMID: 18422355] (ELISA (Standard), N/A)
• Ahmed N, Ratnayake M, Savoldo B, Perlaky L, Dotti G, Wels WS, Bhattacharjee MB, Gilbertson RJ, Shine HD, Weiss HL, Rooney CM, Heslop HE, Gottschalk S Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res., 2007;67(12):5957-64. 2007 [PMID: 17575166] (Flow Cytometry, Human)

FAQs for ErbB2/Her2 (1129-ER). (Showing 1 - 1 of 1 FAQs).

1. I am interested in getting antibodies for HER that would work in flow cytometry. Could you recommend some choices?
   • A list of our ErbB2 antibodies validated for use in flow cytometry can be found here /productsearch/HER2#fq=common_name%3A%22ErbB2%2FHER2%22&fq=category%3A%22Primary%20Antibodies%22&fq=applications%3A%22Flow%20Cytometry%22

Bioinformatics

• Gene Symbol: ERBB2
• Uniprot:
  • NP_004439()